Patent application number | Description | Published |
20080248105 | POLYMORPHIC FORMS OF 6-11 BICYCLIC KETOLIDE DERIVATIVES - The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing the various polymorphic forms in pure form or in combination with one another. The present invention also provides pharmaceutical compositions and formulations comprising the polymorphic and amorphous forms and methods of treating bacterial infections by administering the pharmaceutical compositions to a subject in need of such treatment. | 10-09-2008 |
20080267916 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 10-30-2008 |
20080267918 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 10-30-2008 |
20080274082 | OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 11-06-2008 |
20090005387 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS - The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 01-01-2009 |
20090041721 | ARYLALKOXYL HEPATITIS C VIRUS PROTEASE INHIBITORS - The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-12-2009 |
20090123423 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 05-14-2009 |
20090155210 | OXIMYL HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-18-2009 |
20090180984 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-16-2009 |
20090191151 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of formula I, II and III or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-30-2009 |
20090197888 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 08-06-2009 |
20090202485 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 08-13-2009 |
20090202486 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 08-13-2009 |
20090238794 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-24-2009 |
20090274657 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-05-2009 |
20100003214 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 01-07-2010 |
20100144608 | Macrocyclic hepatitis C serine protease inhibitors - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 06-10-2010 |
20110033420 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-10-2011 |
20110123496 | BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 05-26-2011 |
20120101031 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 04-26-2012 |
20120196792 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 08-02-2012 |
20130144036 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-06-2013 |
20140148573 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 05-29-2014 |
20140287992 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 09-25-2014 |